Research Overview
What a peptide bioregulator is
The Cytomax preparations occupy an unusual position between a defined pharmaceutical and a tissue extract. Each is produced by extracting a low-molecular-weight peptide fraction from a designated organ or tissue of young animals, then purifying away larger proteins, nucleic acids and lipids. What remains is a mixture of short peptides characterised by its source and its size range rather than by a structural formula. Sigumir is the cartilage-directed preparation in that series, sitting alongside members addressed to thymus, pineal, vascular, bronchial and other tissues.
The tissue-specificity hypothesis
Defined analogue as a research tool
- Cartalax (Ala-Glu-Asp-Gly) provides a single, synthesisable sequence for the cartilage context
- A defined tetrapeptide can be characterised by HPLC and mass spectrometry in ways a mixture cannot
- Comparative designs pair extract and synthetic analogue to ask whether activity tracks a single component
- Analytical work on extracts focuses on fraction profile and batch-to-batch consistency
Interpreting a mixture
The scientific limitation is inherent to the format. When the article is a fraction rather than a molecule, batch-to-batch composition can vary with source material and processing, and attributing an observed effect to a specific component is difficult. Researchers working with these preparations generally document the lot in detail, retain reference samples and, where the question permits, run the defined synthetic analogue in parallel so that a mechanistic claim can rest on a known structure.